Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 75Unknown 8Active not recruiting 7Terminated 6Withdrawn 5Approved for marketing 2

Sponsor Class

OTHER 21INDUSTRY 6NIH 3NETWORK 3OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 5CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Brain Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Gefitinib × Clear all
NCT02588261 2024-12-10

SOLAR

Astellas Pharma Inc

Phase 3 Terminated
530 enrolled 25 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03599518 2023-02-08

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 1 Terminated
20 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00536107 2013-10-01

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

AstraZeneca

Phase 4 Terminated
14 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00234468 2011-05-20

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

AstraZeneca

Phase 3 Terminated
490 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00234442 2009-06-30

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

AstraZeneca

Phase 2 Terminated
47 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00237900 2009-04-23

Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer

AstraZeneca

Phase 1/2 Terminated
34 enrolled

Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡